News headlines about MannKind (NASDAQ:MNKD) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. MannKind earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 44.9681238075744 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern’s analysis:
- These Two Updates Caused MannKind’s Stock to Plunge 25.9% in December – Motley Fool (fool.com)
- Do What Institutional Investors Does: MannKind Corporation (MNKD), Simon Property Group, Inc. (SPG) – Market Movers (financialqz.com)
- These Two Updates Caused MannKind's Stock to Plunge 25.9% in December (finance.yahoo.com)
- Silvery Stock-:- MannKind Corporation (NASDAQ:MNKD) – Market Breaking Point (press release) (journalfinance.net)
A number of equities analysts recently issued reports on the company. BidaskClub lowered MannKind from a “hold” rating to a “sell” rating in a research note on Friday, December 22nd. Zacks Investment Research lowered MannKind from a “hold” rating to a “sell” rating in a research note on Wednesday, December 13th. ValuEngine upgraded MannKind from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 30th. HC Wainwright reiterated a “buy” rating on shares of MannKind in a research note on Wednesday, November 8th. Finally, Maxim Group reiterated a “hold” rating on shares of MannKind in a research note on Wednesday, November 1st. Five research analysts have rated the stock with a sell rating, one has issued a hold rating and one has assigned a buy rating to the company’s stock. MannKind presently has an average rating of “Sell” and an average price target of $0.92.
MannKind (NASDAQ:MNKD) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.11). The company had revenue of $2.04 million for the quarter, compared to analysts’ expectations of $2.56 million. MannKind had a negative net margin of 155.83% and a negative return on equity of 24.93%. The business’s quarterly revenue was down 98.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.30 EPS. equities research analysts expect that MannKind will post -1.13 earnings per share for the current fiscal year.
In other MannKind news, Director Kent Kresa bought 166,600 shares of the company’s stock in a transaction dated Friday, October 13th. The shares were purchased at an average cost of $6.00 per share, for a total transaction of $999,600.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Stuart A. Tross bought 39,840 shares of the company’s stock in a transaction dated Thursday, December 21st. The shares were acquired at an average price of $2.52 per share, for a total transaction of $100,396.80. Following the completion of the transaction, the vice president now directly owns 59,840 shares in the company, valued at $150,796.80. The disclosure for this purchase can be found here. Insiders have acquired a total of 214,440 shares of company stock valued at $1,118,317 in the last quarter. Company insiders own 1.10% of the company’s stock.
MannKind Company Profile
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.